YB-1 Oncoprotein Controls PI3K/Akt Pathway by Reducing Pten Protein Level.


Journal

Genes
ISSN: 2073-4425
Titre abrégé: Genes (Basel)
Pays: Switzerland
ID NLM: 101551097

Informations de publication

Date de publication:
29 09 2021
Historique:
received: 21 08 2021
revised: 24 09 2021
accepted: 28 09 2021
entrez: 23 10 2021
pubmed: 24 10 2021
medline: 9 2 2022
Statut: epublish

Résumé

YB-1 is a multifunctional protein overexpressed in many types of cancer. It is a crucial oncoprotein that regulates cancer cell progression and proliferation. Ubiquitously expressed in human cells, YB-1 protein functions are strictly dependent on its subcellular localization. In the cytoplasm, where YB-1 is primarily localized, it regulates mRNA translation and stability. However, in response to stress stimuli and activation of PI3K and RSK signaling, YB-1 moves to the nucleus acting as a prosurvival factor. YB-1 is reported to regulate many cellular signaling pathways in different types of malignancies. Furthermore, several observations also suggest that YB-1 is a sensor of oxidative stress and DNA damage. Here we show that YB-1 reduces PTEN intracellular levels thus leading to PI3K/Akt pathway activation. Remarkably, PTEN reduction mediated by YB-1 overexpression can be observed in human immortalized keratinocytes and HEK293T cells and cannot be reversed by proteasome inhibition. Real-time PCR data indicate that YB-1 silencing up-regulates the PTEN mRNA level. Collectively, these observations indicate that YB-1 negatively controls PTEN at the transcript level and its overexpression could confer survival and proliferative advantage to PTEN proficient cancer cells.

Identifiants

pubmed: 34680946
pii: genes12101551
doi: 10.3390/genes12101551
pmc: PMC8535809
pii:
doi:

Substances chimiques

Y-Box-Binding Protein 1 0
YBX1 protein, human 0
Proto-Oncogene Proteins c-akt EC 2.7.11.1
PTEN Phosphohydrolase EC 3.1.3.67

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Breast Cancer. 2008;15(1):73-8
pubmed: 18224398
Mol Cancer Ther. 2004 Nov;3(11):1485-92
pubmed: 15542787
Cells. 2019 Dec 31;9(1):
pubmed: 31906126
Mol Cell Biol. 2003 Sep;23(17):6139-49
pubmed: 12917336
Biochemistry (Mosc). 2011 Dec;76(13):1402-33
pubmed: 22339596
Cancer Sci. 2019 May;110(5):1536-1543
pubmed: 30903644
Cancers (Basel). 2019 Sep 19;11(9):
pubmed: 31546901
Front Oncol. 2015 Feb 16;5:24
pubmed: 25763354
Mol Cell Biol. 2006 Jan;26(1):277-92
pubmed: 16354698
J Thorac Oncol. 2009 Sep;4(9):1066-74
pubmed: 19648825
Genes (Basel). 2018 Oct 22;9(10):
pubmed: 30360431
Cancer Res. 2007 Oct 1;67(19):8980-4
pubmed: 17908997
Oncogene. 2010 Jan 21;29(3):403-10
pubmed: 19838214
Int J Oncol. 2015 Oct;47(4):1189-202
pubmed: 26315971
Trends Pharmacol Sci. 2011 Mar;32(3):131-40
pubmed: 21236500
J Biol Chem. 1998 May 29;273(22):13375-8
pubmed: 9593664
Cancer Lett. 2012 Jun 28;319(2):125-129
pubmed: 22266095
Nat Med. 2014 Apr;20(4):360-7
pubmed: 24633304
Nat Genet. 2010 May;42(5):454-8
pubmed: 20400965
Oncotarget. 2018 Apr 10;9(27):19039-19049
pubmed: 29721182
PLoS One. 2013 Nov 18;8(11):e80171
pubmed: 24260353
Nat Rev Mol Cell Biol. 2018 Sep;19(9):547-562
pubmed: 29858604
Int J Radiat Oncol Biol Phys. 2021 Feb 1;109(2):567-580
pubmed: 32931865
Cell Commun Signal. 2018 Sep 26;16(1):63
pubmed: 30257675
Cancers (Basel). 2020 Jan 29;12(2):
pubmed: 32013098
Sci Rep. 2017 May 17;7(1):2056
pubmed: 28515422

Auteurs

Antonella Delicato (A)

Department of Biology, University of Naples Federico II, MSA-Via Cinthia, 26-80126 Naples, Italy.

Eleonora Montuori (E)

Department of Biology, University of Naples Federico II, MSA-Via Cinthia, 26-80126 Naples, Italy.

Tiziana Angrisano (T)

Department of Biology, University of Naples Federico II, MSA-Via Cinthia, 26-80126 Naples, Italy.

Alessandra Pollice (A)

Department of Biology, University of Naples Federico II, MSA-Via Cinthia, 26-80126 Naples, Italy.

Viola Calabrò (V)

Department of Biology, University of Naples Federico II, MSA-Via Cinthia, 26-80126 Naples, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH